Table 2.

Neutralizing synergy of p11D7 with plant‐made tixagevimab and plant‐made cilgavimab against the B.1.1.529 variant

mAb Combination	Observed Neutralization (%)	HSA Predicted Neutralization (%)	Loewe Predicted Neutralization (%)
p11D7 + tixagevimab	91.97 ± 2.60	35.58 ± 7.15	40.89 ± 11.29
p11D7 + cilgavimab	68.21 ± 13.60	38.31 ± 12.57	48.98 ± 1.90
tixagevimab + cilgavimab	89.63 ± 2.26	47.50 ± 3.38	50.34 ± 0.55
p11D7 + tixagevimab + cilgavimab	96.59 ± 0.64	47.85 ± 3.04	66.22 ± 5.40

Per cent neutralization was obtained via FFA for each individual and combination of mAbs with each mAb at the concentration that corresponds to the IC₅₀. The per cent neutralization data from each individual mAb was used to calculate the predicted per cent neutralization of the cocktail with the highest single agent (HSA) and Loewe models in SynergyFinder.org, assuming there is no neutralization synergy between mAbs in the cocktail. If the empirically determined observed per cent neutralization value of the cocktail is higher than that predicted by the models, it indicates synergistic interaction of the mAbs in the cocktail. At least two independent experiments with technical triplets were performed for each mAb and mAb combination with SD presented.